keyword
MENU ▼
Read by QxMD icon Read
search

nanoparticle vaccine

keyword
https://www.readbyqxmd.com/read/29778982/efficient-co-delivery-of-neo-epitopes-using-dispersion-stable-layered-double-hydroxide-nanoparticles-for-enhanced-melanoma-immunotherapy
#1
Ling-Xiao Zhang, Xi-Xiu Xie, Dong-Qun Liu, Zhi Ping Xu, Rui-Tian Liu
Cancer immunotherapy has shown tremendous progresses in recent years for various cancers and layered double hydroxide (LDH) nanoparticles are demonstrated as effective adjuvants for protein-based vaccines. This research further shows that the colloidal stability of LDH-based vaccines significantly influences the therapeutic efficacy and LDH nanoparticles are able to adjuvant multiple tumor-associated antigen peptides to provoke strong cell-mediated immune responses for effective inhibition of cancer growth...
May 10, 2018: Biomaterials
https://www.readbyqxmd.com/read/29776611/nasal-delivery-of-chitosan-alginate-nanoparticle-encapsulated-bee-apis-mellifera-venom-promotes-antibody-production-and-viral-clearance-during-porcine-reproductive-and-respiratory-syndrome-virus-infection-by-modulating-t-cell-related-responses
#2
Jina Lee, Yun-Mi Kim, Ju-Heon Kim, Cheong-Weon Cho, Jong-Woon Jeon, Jin-Kyu Park, Sang-Ho Lee, Bock-Gie Jung, Bong-Joo Lee
In this study, we administered specially developed chitosan/alginate nanoparticle encapsulated BV (CH/AL-BV) which has slow-releasing properties and mucosal adhesiveness to pig via nasal route and evaluate whether it can facilitate systemic immune response and improve clearance of porcine reproductive and respiratory syndrome virus (PRRSV). The CH/AL-BV-administered group with PRRSV vaccination showed significantly enhanced Th1-related responses including a high population of CD4+ T lymphocyte and cytokine mRNA levels including interferon-gamma (IFN-γ) and interleukin (IL)-12 and increased PRRSV-specific IgG levels...
June 2018: Veterinary Immunology and Immunopathology
https://www.readbyqxmd.com/read/29771487/cancer-cell-membrane-coated-adjuvant-nanoparticles-with-mannose-modification-for-effective-anticancer-vaccination
#3
Rong Yang, Jun Xu, Ligeng Xu, Xiaoqi Sun, Qian Chen, Yuhuan Zhao, Rui Peng, Zhuang Liu
Tumor vaccines for cancer prevention and treatment have attracted tremendous interests in the area of cancer immunotherapy in recent years. In this work, we present a strategy to construct cancer vaccines by encapsulating immune-adjuvant nanoparticles with cancer cell membrane modified by mannose. Poly (D, L-lactide-co-glycolide) (PLGA) nanoparticles are firstly loaded with toll-like receptor 7 agonist, imiquimod (R837). Those adjuvant nanoparticles (NP-R) are then coated with cancer cell membranes (NP-R@M), whose surface proteins could act as tumor-specific antigens...
May 17, 2018: ACS Nano
https://www.readbyqxmd.com/read/29770135/mucosal-immunity-and-protective-efficacy-of-intranasal-inactivated-influenza-vaccine-is-improved-by-chitosan-nanoparticle-delivery-in-pigs
#4
Santosh Dhakal, Sankar Renu, Shristi Ghimire, Yashavanth Shaan Lakshmanappa, Bradley T Hogshead, Ninoshkaly Feliciano-Ruiz, Fangjia Lu, Harm HogenEsch, Steven Krakowka, Chang Won Lee, Gourapura J Renukaradhya
Annually, swine influenza A virus (SwIAV) causes severe economic loss to swine industry. Currently used inactivated SwIAV vaccines administered by intramuscular injection provide homologous protection, but limited heterologous protection against constantly evolving field viruses, attributable to the induction of inadequate levels of mucosal IgA and cellular immune responses in the respiratory tract. A novel vaccine delivery platform using mucoadhesive chitosan nanoparticles (CNPs) administered through intranasal (IN) route has the potential to elicit strong mucosal and systemic immune responses in pigs...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/29769448/tlr-adjuvanted-nanoparticle-vaccines-differentially-influence-the-quality-and-longevity-of-responses-to-malaria-antigen-pfs25
#5
Elizabeth A Thompson, Sebastian Ols, Kazutoyo Miura, Kelly Rausch, David L Narum, Mats Spångberg, Michal Juraska, Ulrike Wille-Reece, Amy Weiner, Randall F Howard, Carole A Long, Patrick E Duffy, Lloyd Johnston, Conlin P O'Neil, Karin Loré
Transmission-blocking vaccines (TBVs) are considered an integral element of malaria eradication efforts. Despite promising evaluations of Plasmodium falciparum Pfs25-based TBVs in mice, clinical trials have failed to induce robust and long-lived Ab titers, in part due to the poorly immunogenic nature of Pfs25. Using nonhuman primates, we demonstrate that multiple aspects of Pfs25 immunity were enhanced by antigen encapsulation in poly(lactic-co-glycolic acid)-based [(PLGA)-based] synthetic vaccine particles (SVP[Pfs25]) and potent TLR-based adjuvants...
May 17, 2018: JCI Insight
https://www.readbyqxmd.com/read/29760047/nanoparticles-that-reshape-the-tumor-milieu-create-a-therapeutic-window-for-effective-t-cell-therapy-in-solid-malignancies
#6
Fan Zhang, Sirkka B Stephan, Chibawanye I Ene, Tyrel T Smith, Eric C Holland, Matthias T Stephan
A major obstacle to the success rate of chimeric antigen receptor (CAR-) T cell therapy against solid tumors is the microenvironment antagonistic to T cells that solid tumors create. Conventional checkpoint blockade can silence lymphocyte anti-survival pathways activated by tumors, but because they are systemic, these treatments disrupt immune homeostasis and induce autoimmune side effects. Thus, new technologies are required to remodel the tumor milieu without causing systemic toxicities. Here we demonstrate that targeted nanocarriers that deliver a combination of immune-modulatory agents can remove pro-tumor cell populations and simultaneously stimulate anti-tumor effector cells...
May 14, 2018: Cancer Research
https://www.readbyqxmd.com/read/29759379/simultaneous-surface-display-and-cargo-loading-of-encapsulin-nanocompartments-and-their-use-for-rational-vaccine-design
#7
Priscillia Lagoutte, Charlotte Mignon, Gustavo Stadthagen, Supanee Potisopon, Stéphanie Donnat, Jan Mast, Adrien Lugari, Bettina Werle
In the past decades protein nanoparticles have successfully been used for vaccine applications. Their particulate nature and dense repetitive subunit organization makes them perfect carriers for antigen surface display and confers high immunogenicity. Nanoparticles have emerged as excellent candidates for vectorization of biological and immunostimulating molecules. Nanoparticles and biomolecular nanostructures such as ferritins or virus like particles have been used as diagnostic and therapeutic delivery systems, in vaccine development, as nanoreactors, etc...
May 11, 2018: Vaccine
https://www.readbyqxmd.com/read/29746999/characterization-of-rabies-pdna-nanoparticulate-vaccine-in-poloxamer-407-gel
#8
Amit Bansal, Xianfu Wu, Victoria Olson, Martin J D'Souza
Plasmid DNA (pDNA) vaccines have the potential for protection against a wide range of diseases including rabies but are rapid in degradation and poor in uptake by antigen-presenting cells. To overcome the limitations, we fabricated a pDNA nanoparticulate vaccine. The negatively charged pDNA was adsorbed onto the surface of cationic PLGA (poly (d, l-lactide-co-glycolide))-chitosan nanoparticles and were used as a delivery vehicle. To create a hydrogel for sustainable vaccine release, we dispersed the pDNA nanoparticles in poloxamer 407 gel which is liquid at 4 °C and turns into soft gels at 37 °C, providing ease of administration and preventing burst release of pDNA...
May 7, 2018: International Journal of Pharmaceutics
https://www.readbyqxmd.com/read/29741393/molecular-docking-of-immunogenic-peptide-of-toxoplasma-gondii-and-encapsulation-with-polymer-as-vaccine-candidate
#9
Rabia Cakir-Koc, Yasemin Budama-Kilinc, Yagmur Kokcu, Serda Kecel-Gunduz
Toxoplasma gondii is one of the most widely spread parasitic organisms in the world. T. gondii causes primary, chronic infection and mortality. Major surface antigen 1 is the most abundant tachyzoite surface protein and highly conserved between species and causes strong humoural response. Some studies showed that the peptide sequence of surface antigen has immunity. Therefore, tachyzoite surface antigenic peptide sequence is one of the good candidates for vaccine development. However, conformational information and delivery systems are very important parameters for vaccine development...
May 9, 2018: Artificial Cells, Nanomedicine, and Biotechnology
https://www.readbyqxmd.com/read/29740425/induction-of-type-i-interferons-by-therapeutic-nanoparticle-based-vaccination-is-indispensable-to-reinforce-cytotoxic-cd8-t-cell-responses-during-chronic-retroviral-infection
#10
Torben Knuschke, Olga Rotan, Wibke Bayer, Sebastian Kollenda, Julia Dickow, Kathrin Sutter, Wiebke Hansen, Ulf Dittmer, Karl S Lang, Matthias Epple, Jan Buer, Astrid M Westendorf
T cell dysfunction and immunosuppression are characteristic for chronic viral infections and contribute to viral persistence. Overcoming these burdens is the goal of new therapeutic strategies to cure chronic infectious diseases. We recently described that therapeutic vaccination of chronic retrovirus infected mice with a calcium phosphate (CaP) nanoparticle (NP)-based vaccine carrier, functionalized with CpG and viral peptides is able to efficiently reactivate the CD8+ T cell response and improve the eradication of virus infected cells...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/29739835/nucleoside-modified-mrna-vaccines-induce-potent-t-follicular-helper-and-germinal-center-b-cell-responses
#11
Norbert Pardi, Michael J Hogan, Martin S Naradikian, Kaela Parkhouse, Derek W Cain, Letitia Jones, M Anthony Moody, Hans P Verkerke, Arpita Myles, Elinor Willis, Celia C LaBranche, David C Montefiori, Jenna L Lobby, Kevin O Saunders, Hua-Xin Liao, Bette T Korber, Laura L Sutherland, Richard M Scearce, Peter T Hraber, István Tombácz, Hiromi Muramatsu, Houping Ni, Daniel A Balikov, Charles Li, Barbara L Mui, Ying K Tam, Florian Krammer, Katalin Karikó, Patricia Polacino, Laurence C Eisenlohr, Thomas D Madden, Michael J Hope, Mark G Lewis, Kelly K Lee, Shiu-Lok Hu, Scott E Hensley, Michael P Cancro, Barton F Haynes, Drew Weissman
T follicular helper (Tfh) cells are required to develop germinal center (GC) responses and drive immunoglobulin class switch, affinity maturation, and long-term B cell memory. In this study, we characterize a recently developed vaccine platform, nucleoside-modified, purified mRNA encapsulated in lipid nanoparticles (mRNA-LNPs), that induces high levels of Tfh and GC B cells. Intradermal vaccination with nucleoside-modified mRNA-LNPs encoding various viral surface antigens elicited polyfunctional, antigen-specific, CD4+ T cell responses and potent neutralizing antibody responses in mice and nonhuman primates...
May 8, 2018: Journal of Experimental Medicine
https://www.readbyqxmd.com/read/29739720/heterologous-prime-boost-vaccination-with-adenoviral-vector-and-protein-nanoparticles-induces-both-th1-and-th2-responses-against-middle-east-respiratory-syndrome-coronavirus
#12
Seo-Yeon Jung, Kyung Won Kang, Eun-Young Lee, Dong-Won Seo, Hong-Lim Kim, Hak Kim, TaeWoo Kwon, Hye-Lim Park, Hun Kim, Sang-Myeong Lee, Jae-Hwan Nam
The Middle East respiratory syndrome coronavirus (MERS-CoV) is a highly pathogenic and zoonotic virus with a fatality rate in humans of over 35%. Although several vaccine candidates have been developed, there is still no clinically available vaccine for MERS-CoV. In this study, we developed two types of MERS-CoV vaccines: a recombinant adenovirus serotype 5 encoding the MERS-CoV spike gene (Ad5/MERS) and spike protein nanoparticles formulated with aluminum (alum) adjuvant. Next, we tested a heterologous prime-boost vaccine strategy, which compared priming with Ad5/MERS and boosting with spike protein nanoparticles and vice versa, with homologous prime-boost vaccination comprising priming and boosting with either spike protein nanoparticles or Ad5/MERS...
May 5, 2018: Vaccine
https://www.readbyqxmd.com/read/29737353/induction-of-necrotic-cell-death-and-activation-of-sting-in-the-tumor-microenvironment-via-cationic-silica-nanoparticles-leading-to-enhanced-antitumor-immunity
#13
Myunggi An, Chunsong Yu, Jingchao Xi, Joyce Reyes, Guangzhao Mao, Wei-Zen Wei, Haipeng Liu
Nanotechnology has demonstrated tremendous clinical utility, with potential applications in cancer immunotherapy. Although nanoparticles with intrinsic cytotoxicity are often considered unsuitable for clinical applications, such toxicity may be harnessed in the fight against cancer. Nanoparticle-associated toxicity can induce acute necrotic cell death, releasing tumor-associated antigens which may be captured by antigen-presenting cells to initiate or amplify tumor immunity. To test this hypothesis, cytotoxic cationic silica nanoparticles (CSiNPs) were directly administered into B16F10 melanoma implanted in C57BL/6 mice...
May 8, 2018: Nanoscale
https://www.readbyqxmd.com/read/29732445/radiation-therapy-combined-with-cowpea-mosaic-virus-nanoparticle-in-situ-vaccination-initiates-immune-mediated-tumor-regression
#14
Ravi Patel, Anna E Czapar, Steven Fiering, Nancy L Oleinick, Nicole F Steinmetz
Epithelial ovarian cancer is a deadly gynecologic malignancy because of its late detection, usually after local and distant metastatic spread. These cancers develop resistance to traditional chemotherapeutic agents; therefore, the development of next-generation immunotherapeutic approaches may have a significant promise in improving outcomes. A novel immunotherapeutic approach utilizing combination radiation therapy (RT) with immunostimulatory cowpea mosaic virus (CPMV) was tested in a preclinical syngeneic mouse model of ovarian carcinoma...
April 30, 2018: ACS Omega
https://www.readbyqxmd.com/read/29728911/nanoparticle-vaccines-against-viral-infections
#15
REVIEW
Fernando B Sulczewski, Raquel B Liszbinski, Pedro R T Romão, Luiz Carlos Rodrigues Junior
Despite numerous efforts, we still do not have prophylactic vaccines for many clinically relevant viruses, such as HIV, hepatitis C virus, Zika virus, and respiratory syncytial virus. Several factors have contributed to the current lack of effective vaccines, including the high rate of viral mutation, low immunogenicity of recombinant viral antigens, instability of viral antigenic proteins administered in vivo, sophisticated mechanisms of viral immune evasion, and inefficient induction of mucosal immunity by vaccine models studied to date...
May 4, 2018: Archives of Virology
https://www.readbyqxmd.com/read/29726120/nanoscale-platforms-for-messenger-rna-delivery
#16
REVIEW
Bin Li, Xinfu Zhang, Yizhou Dong
Messenger RNA (mRNA) has become a promising class of drugs for diverse therapeutic applications in the past few years. A series of clinical trials are ongoing or will be initiated in the near future for the treatment of a variety of diseases. Currently, mRNA-based therapeutics mainly focuses on ex vivo transfection and local administration in clinical studies. Efficient and safe delivery of therapeutically relevant mRNAs remains one of the major challenges for their broad applications in humans. Thus, effective delivery systems are urgently needed to overcome this limitation...
May 4, 2018: Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology
https://www.readbyqxmd.com/read/29721531/extra-large-pore-mesoporous-silica-nanoparticles-enabling-co-delivery-of-high-amounts-of-protein-antigen-and-toll-like-receptor-9-agonist-for-enhanced-cancer-vaccine-efficacy
#17
Bong Geun Cha, Ji Hoon Jeong, Jaeyun Kim
Cancer vaccine aims to invoke antitumor adaptive immune responses to detect and eliminate tumors. However, the current dendritic cells (DCs)-based cancer vaccines have several limitations that are mostly derived from the ex vivo culture of patient DCs. To circumvent the limitations, direct activation and maturation of host DCs using antigen-carrying materials, without the need for isolation of DCs from patients, are required. In this study, we demonstrate the synthesis of extra-large pore mesoporous silica nanoparticles (XL-MSNs) and their use as a prophylactic cancer vaccine through the delivery of cancer antigen and danger signal to host DCs in the draining lymph nodes...
April 25, 2018: ACS Central Science
https://www.readbyqxmd.com/read/29720976/carbonate-apatite-nanoparticles-act-as-potent-vaccine-adjuvant-delivery-vehicles-by-enhancing-cytokine-production-induced-by-encapsulated-cytosine-phosphate-guanine-oligodeoxynucleotides
#18
Hideki Takahashi, Kazuki Misato, Taiki Aoshi, Yasuyuki Yamamoto, Yui Kubota, Xin Wu, Etsushi Kuroda, Ken J Ishii, Hirofumi Yamamoto, Yasuo Yoshioka
Vaccine adjuvants that can induce not only antigen-specific antibody responses but also Th1-type immune responses and CD8+ cytotoxic T lymphocyte responses are needed for the development of vaccines against infectious diseases and cancer. Of many available adjuvants, oligodeoxynucleotides (ODNs) with unmethylated cytosine-phosphate-guanine (CpG) motifs are the most promising for inducing the necessary immune responses, and these adjuvants are currently under clinical trials in humans. However, the development of novel delivery vehicles that enhance the adjuvant effects of CpG ODNs, subsequently increasing the production of cytokines such as type-I interferons (IFNs), is highly desirable...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/29713168/curdlan-sulfate-o-linked-quaternized-chitosan-nanoparticles-potential-adjuvants-to-improve-the-immunogenicity-of-exogenous-antigens-via-intranasal-vaccination
#19
Shu Zhang, Shengshi Huang, Lu Lu, Xinlei Song, Pingli Li, Fengshan Wang
Introduction: The development of ideal vaccine adjuvants for intranasal vaccination can provide convenience for many vaccinations. As an ideal intranasal vaccine adjuvant, it should have the properties of assisting soluble antigens to pass the mucosal barrier and potentiating both systemic and mucosal immunity via nasal administration. Methods: By using the advantages of polysaccharides, which can promote both T-helper 1 and 2 responses, curdlan sulfate (CS)- O -(2-hydroxyl)propyl-3-trimethyl ammonium chitosan chloride ( O -HTCC) nanoparticles were prepared by interacting CS with O -HTCC, and the adjuvancy of the nanoparticles was investigated...
2018: International Journal of Nanomedicine
https://www.readbyqxmd.com/read/29701995/optimization-of-surface-display-of-denv2-e-protein-on-a-nanoparticle-to-induce-virus-specific-neutralizing-antibody-responses
#20
Jason Coffman, Stefan W Metz, Alexander Brackbill, Molly K Paul, Michael J Miley, Joseph M DeSimone, J Christopher Luft, Aravinda deSilva, Shaomin Tian
The dengue virus (DENV) causes over 350 million infections, resulting in ~25,000 deaths per year globally. An effective dengue vaccine requires generation of strong and balanced neutralizing antibodies against all four antigenically distinct serotypes of DENV. The leading live-attenuated tetravalent dengue virus vaccine, Dengvaxia, has shown only partial efficacy, with an unbalanced immune response across the four serotypes , and is not recommended for the naïve population. DENV subunit vaccine platforms are being developed because they provide a strong safety profile and are expected to avoid the unbalanced immunization issues associated with live multi-valent vaccines...
April 27, 2018: Bioconjugate Chemistry
keyword
keyword
84913
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"